EP3952840A4 - Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents
Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Download PDFInfo
- Publication number
- EP3952840A4 EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- methods
- pharmaceutical compositions
- cognitive disorders
- mental behavior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000003340 mental effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/027293 WO2020209872A1 (fr) | 2019-04-12 | 2019-04-12 | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3952840A1 EP3952840A1 (fr) | 2022-02-16 |
| EP3952840A4 true EP3952840A4 (fr) | 2022-11-23 |
Family
ID=72751206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19924315.5A Pending EP3952840A4 (fr) | 2019-04-12 | 2019-04-12 | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3952840A4 (fr) |
| JP (1) | JP7365426B2 (fr) |
| CN (1) | CN113939276A (fr) |
| AU (1) | AU2019445048A1 (fr) |
| CA (1) | CA3136633A1 (fr) |
| WO (1) | WO2020209872A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| AU2019443520A1 (en) * | 2019-04-30 | 2021-12-23 | La Pharma Tech Inc. | A method of treating mental, behavioral, cognitive disorders |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2377557T (lt) * | 2004-11-24 | 2017-02-10 | Meda Pharmaceuticals Inc. | Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai |
| WO2014018563A2 (fr) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés pour le traitement du cancer |
| WO2018081508A1 (fr) * | 2016-10-28 | 2018-05-03 | Chase Pharmaceutical Corporation | Combinaisons et utilisation de mémantine |
| JP7198575B2 (ja) * | 2017-07-11 | 2023-01-04 | キョーリンリメディオ株式会社 | メマンチン塩酸塩含有口腔内崩壊錠 |
-
2019
- 2019-04-12 WO PCT/US2019/027293 patent/WO2020209872A1/fr not_active Ceased
- 2019-04-12 CN CN201980095322.XA patent/CN113939276A/zh active Pending
- 2019-04-12 AU AU2019445048A patent/AU2019445048A1/en not_active Abandoned
- 2019-04-12 CA CA3136633A patent/CA3136633A1/fr active Pending
- 2019-04-12 EP EP19924315.5A patent/EP3952840A4/fr active Pending
- 2019-04-12 JP JP2021556914A patent/JP7365426B2/ja active Active
Non-Patent Citations (2)
| Title |
|---|
| AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 * |
| TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3952840A1 (fr) | 2022-02-16 |
| CA3136633A1 (fr) | 2020-10-15 |
| WO2020209872A1 (fr) | 2020-10-15 |
| CN113939276A (zh) | 2022-01-14 |
| JP7365426B2 (ja) | 2023-10-19 |
| AU2019445048A1 (en) | 2021-12-02 |
| JP2022535644A (ja) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3952840A4 (fr) | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs | |
| EP3931189A4 (fr) | Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau | |
| EP3750887C0 (fr) | Dérivés de biaryle et leur application pharmaceutique pour le traitement des maladies médiées par la voie du signal pd-1/pd-l1 | |
| EP3490603A4 (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| EP3507371A4 (fr) | Méthodes et compositions pour traiter des maladies et des troubles du système nerveux | |
| EP3826666A4 (fr) | Compositions et méthodes de traitement de maladies associées à la nrp2 | |
| EP3969597A4 (fr) | Compositions et procédés pour le traitement de maladies médiées par l'atpase | |
| EP3972691A4 (fr) | Méthodes et compositions pharmaceutiques pour traiter une surdose de médicament | |
| EP3621593C0 (fr) | Compositions pharmaceutiques et méthodes de traitement de maladies cardiovasculaires | |
| EP3902525A4 (fr) | Compositions pharmaceutiques ophtalmiques et procédés de traitement d'une maladie de surface oculaire | |
| EP4008718C0 (fr) | Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune | |
| EP3818085A4 (fr) | Compositions et leurs utilisations pour traiter une maladie ou un état pathologique | |
| EP4384219A4 (fr) | Compositions, posologies et méthodes pour le traitement d'une maladie oculaire thyroïdienne | |
| EP3689875A4 (fr) | Utilisation de triazolopyrimidine, de composés de triazolopyridine et d'une composition de ceux-ci pour le traitement de maladies médiées par prc2 | |
| EP3920898C0 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| EP3952881A4 (fr) | Compositions et procédés pour le traitement d'inconfort des lentilles de contact | |
| EP3813793A4 (fr) | Composition pour le traitement de l'hyperémie oculaire et procédé de traitement de l'hyperémie oculaire au moyen de celle-ci | |
| EP3979996A4 (fr) | Méthodes et compositions de traitement de troubles de la vue | |
| EP3636281A4 (fr) | Méthode de traitement de la dépression, et composition pharmaceutique | |
| EP3755319A4 (fr) | Composés et compositions pour le traitement de troubles musculaires | |
| EP3960858C0 (fr) | Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison | |
| EP3488850A4 (fr) | Nouvelle application de gzd824 dans le traitement de la leucémie lymphoblastique. | |
| EP4058017A4 (fr) | Formulations médicamenteuses et méthodes de traitement de troubles métaboliques | |
| EP3610879A4 (fr) | Composition de traitement et/ou de prévention de la maladie d'alzheimer | |
| EP3840745A4 (fr) | Méthodes et compositions pour medicaments permettant de traiter des maladies ophthalmiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211111 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20221024 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20221018BHEP Ipc: A61K 47/00 20060101ALI20221018BHEP Ipc: A61K 31/495 20060101ALI20221018BHEP Ipc: A61K 31/55 20060101ALI20221018BHEP Ipc: A61K 31/13 20060101ALI20221018BHEP Ipc: A61K 9/48 20060101ALI20221018BHEP Ipc: A61K 9/20 20060101ALI20221018BHEP Ipc: A61K 9/14 20060101ALI20221018BHEP Ipc: A61K 9/10 20060101ALI20221018BHEP Ipc: A61K 9/08 20060101AFI20221018BHEP |